Observational studyPediatric nephrology (Berlin, Germany)2021
Fluid restriction versus volume expansion in children with diarrhea-associated HUS: a retrospective observational study.
Observational study in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Impact of early volume expansion on severe long-term kidney sequelae in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Pediatric Hemolytic Uremic Syndrome in North-Eastern Germany During the STEC O45:H2 Outbreak in 2025: Clinical Features and Short-Term Outcomes.Open forum infectious diseases · 2026Article
- Acute neurologic clinical manifestations and outcomes in children with thrombotic microangiopathies in paediatric intensive care units.European journal of pediatrics · 2026Observational
- Bloody diarrhea, STEC infection, and HUS in the molecular microbiology era.Pediatric nephrology (Berlin, Germany) · 2026Review
- Long-term outcomes of volume expansion treatment in diarrhea-associated hemolytic uremic syndrome: a six-year follow-up.Pediatric nephrology (Berlin, Germany) · 2026Article
- Pericardial effusion in pediatric Shiga toxin-producing E. coli hemolytic uremic syndrome: a French multicentre study.Pediatric nephrology (Berlin, Germany) · 2026Article
- Volume expansion mitigates Shiga toxin-producing E. coli-hemolytic uremic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2024Article
- Lung Ultrasound to Evaluate Fluid Status and Optimize Early Volume-Expansion Therapy in Children with Shiga Toxin-Producing Escherichia Coli-Haemolytic Uremic Syndrome: A Pilot Study.Journal of clinical medicine · 2024Article
- Article
- Fluid balance in pediatric critically ill patients (with and without kidney dysfunction).Current opinion in critical care · 2022Review
- Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS).Pediatric nephrology (Berlin, Germany) · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFifty percent of patients with typical diarrhea-associated hemolytic uremic syndrome (D+HUS) require kidney replacement therapy (KRT). In these patients, dehydration worsens disease prognosis. We evaluated dialysis requirement, presence of seizures, and mortality rate among patients diagnosed with D+HUS treated with volume expansion (VE) versus fluid restriction (FR).
methodsThirty-five patients with D+HUS were enrolled; 16 received VE and 19 were historical patients who received conventional FR.
resultsUpon admission or during treatment, neither group presented evidence of fluid overload. The VE group received higher volumes of saline (VE 27 ml/kg [10-30] over a 3-h period vs. FR 0 ml), had higher urine output after 12 h (VE vs. FR: OR 6.2 [1.2-41.6], P = 0.03), and required less dialysis (VE 2 [12.5%, CI 95% 0-29] vs. FR 9 [47.4%, CI 95% 24-70], P = 0.035). The VE group had an absolute risk reduction of 0.34 (CI 95% 0.07-0.63); hence, three patients treated with VE were required to avoid one KRT. VE also corrected initial hyponatremia and maintained serum sodium within normal ranges. No statistical differences were observed regarding number of patients with seizures (P = 0.08) or mortality (P = 1.0).
conclusionsVE markedly reduces the number of patients requiring KRT and keeps serum sodium within a normal range. We propose to initially hydrate every patient with D+HUS and without signs of fluid overload, with 10 ml/kg/h 0.9% saline solution IV, over a 3-h period. Afterwards, if urine output is ≥ 0.5 ml/kg/h, it is recommended to not dialyze and continue IV hydration schedule with isotonic (D5) saline solution, according to their needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.